6 results on '"Lopalco, Lucia"'
Search Results
2. Additional file 3 of Different decay of antibody response and VOC sensitivity in na��ve and previously infected subjects at 15 weeks following vaccination with BNT162b2
- Author
-
Siracusano, Gabriel, Ruggiero, Alessandra, Bisoffi, Zeno, Piubelli, Chiara, Carbonare, Luca Dalle, Valenti, Maria Teresa, Mayora-Neto, Martin, Temperton, Nigel, Lopalco, Lucia, and Zipeto, Donato
- Abstract
Additional file 3: Table S2. Correlations between anti-RBD IgG loads and IC50 values for each variant in previously infected patients.
- Published
- 2022
- Full Text
- View/download PDF
3. Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations
- Author
-
Pastori, Claudia, Diomede, Lorenzo, Venuti, Assunta, Fisher, Gregory, Jarvik, Jonathan, Bomsel, Morgane, Sanvito, Francesca, and Lopalco, Lucia
- Subjects
FOS: Biological sciences ,69999 Biological Sciences not elsewhere classified - Abstract
UNLABELLED: The chemokine receptor CCR5 is essential for HIV infection and is thus a potential target for vaccine development. However, because CCR5 is a host protein, generation of anti-CCR5 antibodies requires the breaking of immune tolerance and thus carries the risk of autoimmune responses. In this study, performed in mice, we compared 3 different immunogens representing surface domains of murine CCR5, 4 different adjuvants, and 13 different immunization protocols, with the goal of eliciting HIV-blocking activity without inducing autoimmune dysfunction. In all cases the CCR5 sequences were presented as fusions to the Flock House virus (FHV) capsid precursor protein. We found that systemic immunization and mucosal boosting elicited CCR5-specific antibodies and achieved consistent priming in Peyer's patches, where most cells showed a phenotype corresponding to activated B cells and secreted high levels of IgA, representing up to one-third of the total HIV-blocking activity. Histopathological analysis revealed mild to moderate chronic inflammation in some tissues but failed in reporting signs of autoimmune dysfunction associated with immunizations. Antisera against immunogens representing the N terminus and extracellular loops 1 and 2 (Nter1 and ECL1 and ECL2) of CCR5 were generated. All showed specific anti-HIV activity, which was stronger in the anti-ECL1 and -ECL2 sera than in the anti-Nter sera. ECL1 and ECL2 antisera induced nearly complete long-lasting CCR5 downregulation of the receptor, and especially, their IgG-depleted fractions prevented HIV infection in neutralization and transcytosis assays. In conclusion, the ECL1 and ECL2 domains could offer a promising path to achieve significant anti-HIV activity in vivo. IMPORTANCE: The study was the first to adopt a systematic strategy to compare the immunogenicities of all extracellular domains of the CCR5 molecule and to set optimal conditions leading to generation of specific antibodies in the mouse model. There were several relevant findings, which could be translated into human trials. (i) Prime (systemic) and boost (mucosal) immunization is the best protocol to induce anti-self antibodies with the expected properties. (ii) Aluminum is the best adjuvant in mice and thus can be easily used in nonhuman primates (NHP) and humans. (iii) The Flock House virus (FHV) system represents a valid delivery system, as the structure is well known and is not pathogenic for humans, and it is possible to introduce constrained regions able to elicit antibodies that recognize conformational epitopes. (iv) The best CCR5 vaccine candidate should include either extracellular loop 1 or 2 (ECL1 or ECL2), but not N terminus domains.
- Published
- 2014
- Full Text
- View/download PDF
4. Short Communication: Decreased Plasma Calcitonin Gene-Related Peptide as a Novel Biomarker for HIV-1 Disease Progression
- Author
-
Lucia Lopalco, Morgane Bomsel, Yonatan Ganor, Gabriel Siracusano, Caterina Uberti-Foppa, Bomsel, Morgane, Lopalco, Lucia, Uberti-Foppa, Caterina, Siracusano, Gabriel, Ganor, Yonatan, Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of immunology and Infectious Deseases, San Raffaele Scientific Institute, Institut Cochin (IC UM3 (UMR 8104 / U1016)), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)
- Subjects
0301 basic medicine ,Cart ,medicine.medical_specialty ,Calcitonin Gene-Related Peptide ,[SDV]Life Sciences [q-bio] ,T cell ,Immunology ,Neuropeptide ,HIV Infections ,Vasodilation ,Calcitonin gene-related peptide ,calcitonin gene-related peptide ,Immunoenzyme Techniques ,Plasma ,03 medical and health sciences ,0302 clinical medicine ,Virology ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,primary and chronic HIV-1 infection ,ComputingMilieux_MISCELLANEOUS ,business.industry ,elite controller ,long-term nonprogressor ,virus diseases ,plasma biomarker ,Viral Load ,CD4 Lymphocyte Count ,3. Good health ,030104 developmental biology ,Infectious Diseases ,Endocrinology ,medicine.anatomical_structure ,nervous system ,Calcitonin ,exposed seronegative ,Disease Progression ,combination antiretroviral therapy ,Biomarker (medicine) ,business ,Viral load ,Biomarkers - Abstract
HIV-1 mucosal transmission in genital epithelia occurs through infection of Langerhans cells and subsequent transinfection of CD4+ T cells. We previously reported that the vasodilator neuropeptide calcitonin gene-related peptide (CGRP), secreted upon activation of sensory peripheral neurons that innervate all mucosal epithelia, significantly inhibits transinfection. To investigate the association between CGRP and HIV-1 during infection, we evaluated circulating CGRP levels in HIV-1-infected patients. Plasma was obtained from combination antiretroviral therapy (cART)-naive or cART-treated patients with primary/acute (PHI) or chronic (CHI) HIV-1 infection, as well as from individuals who naturally control HIV-1 infection, namely exposed seronegatives (ESNs), elite controllers (ECs), and long-term nonprogressors (LTNPs). CGRP plasma levels were measured using an enzyme immunoassay. Compared with healthy HIV-1-negative controls, CGRP plasma levels significantly decreased in PHI patients and even further in CHI patients, but remained unchanged in ESNs, ECs, and LTNPs. Moreover, CGRP plasma levels were restored to baseline upon cART in both PHI and CHI. Finally, CGRP plasma levels directly correlated with CD4+ T cell counts and inversely with viral loads. Altogether, CGRP could serve as a novel diagnostic plasma biomarker for progression of HIV-1 infection. Moreover, administration of CGRP to cART-naive HIV-1-infected patients, to compensate for CGRP decline, could help controlling on-going HIV-1 infection.
- Published
- 2019
5. A Nonparametric Procedure for Defining a New Humoral Immunologic Profile in a Pilot Study on HIV Infected Patients
- Author
-
Massimo Galli, L. Diomede, Lucia Lopalco, Clelia Di Serio, Chiara Brombin, Anne Sophie Drillet, Claudia Pastori, Daniela Tudor, Morgane Bomsel, Elena Poli, Caterina Uberti-Foppa, Agostino Riva, Brombin, Chiara, Diomede, Lorenzo, Tudor, Daniela, Drillet Anne, Sophie, Pastori, Claudia, Poli, Elena, Riva, Agostino, UBERTI FOPPA, Caterina, Galli, Massimo, DI SERIO, Mariaclelia, Bomsel, Morgane, and Lopalco, Lucia
- Subjects
Male ,Epidemiology ,lcsh:Medicine ,HIV Infections ,Pilot Projects ,HIV Envelope Protein gp120 ,Epitope ,Immunoglobulin G ,Pathology ,Young adult ,lcsh:Science ,Antibody-dependent cell-mediated cytotoxicity ,Multidisciplinary ,biology ,Statistics ,virus diseases ,Middle Aged ,HIV Envelope Protein gp41 ,AIDS ,HIV epidemiology ,Medicine ,Infectious diseases ,HIV clinical manifestations ,Female ,Antibody ,Research Article ,Adult ,Adolescent ,Clinical Research Design ,Immunology ,Sexually Transmitted Diseases ,Viral diseases ,Biostatistics ,Microbiology ,Virus ,Young Adult ,Acquired immunodeficiency syndrome (AIDS) ,Diagnostic Medicine ,Virology ,medicine ,Humans ,Statistical Methods ,Biology ,Aged ,Host Cells ,lcsh:R ,Immunity ,HIV ,medicine.disease ,CD4 Lymphocyte Count ,Immunity, Humoral ,Immunoglobulin A ,Biomarker Epidemiology ,Humoral Immunity ,Humoral immunity ,biology.protein ,Clinical Immunology ,lcsh:Q ,Viral Transmission and Infection ,Mathematics ,Biomarkers ,General Pathology - Abstract
This work aims at identifying a set of humoral immunologic parameters that improve prediction of the activation process in HIV patients. Starting from the well-known impact of humoral immunity in HIV infection, there is still a lack of knowledge in defining the role of the modulation of functional activity and titers of serum antibodies from early stage of infection to the development of AIDS. We propose an integrated approach that combines humoral and clinical parameters in defining the host immunity, implementing algorithms associated with virus control. A number of humoral parameters were simultaneously evaluated in a whole range of serum samples from HIV-positive patients. This issue has been afforded accounting for estimation problems typically related to "feasibility" studies where small sample size in each group and large number of parameters are jointly estimated. We used nonparametric statistical procedures to identify biomarkers in our study which included 42 subjects stratified on five different stages of HIV infection, i.e., Elite Controllers (EC), Long Term Non Progressors (LTNP), HAART, AIDS and Acute Infection (AI). The main goal of the paper is to illustrate a novel profiling method for helping to design a further confirmatory study. A set of seventeen different HIV-specific blood humoral factors were analyzed in all subjects, i.e. IgG and IgA to gp120IIIB, to gp120Bal, to whole gp41, to P1 and T20 gp41 epitopes of the MPER-HR2 region, to QARILAV gp41 epitope of the HR1 region and to CCR5; neutralization activity against five different virus strains and ADCC were also evaluated. Patients were selected on the basis of CD4 cell counts, HIV/RNA and clinical status. The Classification and Regression Trees (CART) approach has been used to uncover specific patterns of humoral parameters in different stages of HIV disease. Virus neutralization of primary virus strains and antibodies to gp41 were required to classify patients, suggesting that clinical profiles strongly rely on functional activity against HIV.
- Published
- 2013
6. Unsung Hero Robert C. Gallo
- Author
-
Abbadessa, G, Accolla, R, Aiuti, F, Albini, A, Aldovini, A, Alfano, M, Antonelli, G, Bartholomew, C, Bentwich, Z, Bertazzoni, U, Berzofsky, Ja, Biberfeld, P, Boeri, E, Buonaguro, L, Buonaguro, Fm, Bukrinsky, M, Burny, A, Caruso, A, Cassol, S, Chandra, P, CECCHERINI NELLI, L, CHIECO BIANCHI, L, Clerici, M, COLOMBINI HATCH, S, Giuli, De, Morghen, C, DE MARIA, A, DE ROSSI, A, Dierich, M, DELLA FAVERA, R, Dolei, A, Douek, D, Erfle, V, Felber, B, Fiorentini, S, Franchini, G, Gershoni, Jm, Gotch, F, Green, P, Greene, Wc, Hall, W, Haseltine, W, Jacobson, S, Kallings, Lo, Kalyanaraman, Vs, Katinger, H, Khalili, K, Klein, G, Klein, E, Klotman, M, Klotman, P, Kotler, M, Kurth, R, Lafeuillade, A, LA PLACA, M, Lewis, J, Lillo, F, Lisziewicz, J, Lomonico, A, Lopalco, L, Lori, F, Lusso, P, Macchi, B, Malim, M, Margolis, L, Markham, Pd, Mcclure, M, Miller, N, Mingari, Mc, Moretta, L, Noonan, D, O'Brien, S, Okamoto, T, Pal, R, Palese, P, Panet, A, Pantaleo, G, Pavlakis, G, Pistello, M, Plotkin, S, Poli, G, Pomerantz, R, Radaelli, A, Robertguroff, M, Roederer, M, Sarngadharan, Mg, Schols, D, Secchiero, P, Shearer, G, Siccardi, A, Stevenson, M, Svoboda, J, Tartaglia, J, Torelli, G, Tornesello, Ml, Tschachler, E, Vaccarezza, Mauro, Vallbracht, A, VAN LUNZEN, J, Varnier, O, Vicenzi, E, Von, Melchner, H, Witz, I, Zagury, D, Zagury, Jf, Zauli, G, Zipeto, D., Abbadessa G, Accolla A, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofski JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatc S, De Giuli Morghen C, De Maria A, De Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalianaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, malim M, margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis J, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robert-Guroff M, Roederer M, Sarnagadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, Van Lunzen J, Varnier O, Vicenzi E, Von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D., Abbadessa, Giovanni, Accolla, Roberto, Aiuti, Fernando, Albini, Adriana, Aldovini, Anna, Alfano, Massimo, Antonelli, Guido, Bartholomew, Courtenay, Bentwich, Zvi, Bertazzoni, Umberto, Berzofsky Jay, A., Biberfeld, Peter, Boeri, Enzo, Buonaguro, Luigi, Buonaguro Franco, M., Bukrinsky, Michael, Burny, Arsene, Caruso, Arnaldo, Cassol, Sharon, Chandra, Prakash, Ceccherini Nelli, Luca, Chieco Bianchi, Luigi, Clerici, Mario, Colombini Hatch, Sandra, Morghen Carlo De, Giuli, De Maria, Andrea, De Rossi, Anita, Dierich, Manfred, Della Favera, Riccardo, Dolei, Antonina, Douek, Daniel, Erfle, Volker, Felber, Barbara, Fiorentini, Simona, Franchini, Genoveffa, Gershoni Jonathan, M., Gotch, France, Green, Patrick, Greene Warner, C., Hall, William, Haseltine, William, Jacobson, Stephen, Kallings Lars, O., Kalyanaraman Vaniambadi, S., Katinger, Hermann, Khalili, Kamel, Klein, George, Klein, Eva, Klotman, Mary, Klotman, Paul, Kotler, Moshe, Kurth, Reinhard, Lafeuillade, Alain, La Placa, Michelangelo, Lewis, Jonathan, Lillo, Flavia, Lisziewicz, Julianna, Lomonico, Anita, Lopalco, Lucia, Lori, Franco, Lusso, Paolo, Macchi, Beatrice, Malim, Michael, Margolis, Leonid, Markham Phillip, D., Mcclure, Myra, Miller, Nancy, Mingari Maria, C., Moretta, Lorenzo, Noonan, Dougla, O'Brien, Steve, Okamoto, Takashi, Pal, Ranajit, Palese, Peter, Panet, Amo, Pantaleo, Giuseppe, Pavlakis, George, Pistello, Mauro, Plotkin, Stanley, Poli, Guido, Pomerantz, Roger, Radaelli, Antonia, Robert Guroff, Marjorie, Roederer, Mario, Sarngadharan Mangalasseril, G., Schols, Dominique, Secchiero, Paola, Shearer, Gene, Siccardi, Antonio, Stevenson, Mario, Svoboda, Jan, Tartaglia, Jim, Torelli, Giuseppe, Tornesello Maria, Lina, Tschachler, Erwin, Vaccarezza, Mauro, Vallbracht, Angelika, Van Lunzen, Jan, Varnier, Oliviero, Vicenzi, Elisa, Von Melchner, Harald, Witz, Isaac, Zagury, Daniel, Zagury Jean, Francoi, Zauli, Giorgio, and Zipeto, Donato
- Subjects
History ,education ,Immunology ,Acquired Immunodeficiency Syndrome ,HIV-1 ,20th Century ,21st Century ,Humans ,Nobel Prize ,United States ,NO ,HIV Research ,Acquired immunodeficiency syndrome (AIDS) ,medicine ,HERO ,health care economics and organizations ,Multidisciplinary ,integumentary system ,Philosophy ,medicine.disease ,humanities ,AIDS ,Harm ,Classics - Abstract
Awarding the Nobel prize in physiology or medicine to Francoise Barre-Sinoussi and Luc Montagnier for the discovery of HIV-1, the causative agent of AIDS ([1][1]), is timely given the harm that the virus continues to inflict on the people of the world. While these awardees fully deserve the award
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.